Breast Cancer Deubiquitinating Enzyme (DUB) Inhibitor Profiling: Fixed-cell GR measures of 21 breast cell lines to 32 small molecule perturbagens. Dataset 2 of 2: Calculated dose response metrics. - Dataset (ID:20351)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Treatment Duration | GR50 | GRmax | GR_AOC | GEC50 | GRinf | hGR |
|---|---|---|---|---|---|---|---|---|
| HCC1806 | z-VAE(OMe)-fmk | 72 | inf | 0.9581 | 0.0231 | 0.0000 | 0.9783 | 0.0100 |
| BT-20 | HY-17542 | 72 | inf | 1.0099 | -0.0181 | 0.0000 | 1.0000 | 0.0100 |
| CAMA-1 | 5-(4-fluorophenyl)-3-hydroxy-4-(5-methyl-2-furoyl)-1-(3-pyridinylmethyl)-1,5-dihydro-2H-pyrrol-2-one | 72 | inf | 0.9375 | 0.0403 | 0.0000 | 0.9497 | 0.0100 |
| CAMA-1 | STK547622 | 72 | inf | 0.8258 | 0.0467 | 0.0000 | 0.9496 | 0.0100 |
| HCC1419 | z-VAE(OMe)-fmk | 72 | inf | 0.9275 | 0.0463 | 0.0000 | 0.9622 | 0.0100 |
| BT-20 | z-VAE(OMe)-fmk | 72 | inf | 0.9762 | 0.0198 | 0.0000 | 0.9890 | 0.0100 |
| BT-20 | 5-(4-fluorophenyl)-3-hydroxy-4-(5-methyl-2-furoyl)-1-(3-pyridinylmethyl)-1,5-dihydro-2H-pyrrol-2-one | 72 | inf | 1.0460 | 0.0369 | 0.0000 | 0.9732 | 0.0100 |
| BT-549 | z-VAE(OMe)-fmk | 72 | inf | 0.9727 | 0.0182 | 0.0000 | 0.9828 | 0.0100 |
| HCC1500 | IU1 | 72 | inf | 0.6977 | 0.0082 | 0.0000 | 0.9531 | 0.0100 |
| BT-20 | SB1-F-22 | 72 | inf | 0.8486 | -0.0325 | 0.0000 | 1.0000 | 0.0100 |
| HCC1419 | STK547622 | 72 | inf | 1.0781 | 0.0128 | 0.0000 | 1.0000 | 0.0100 |
| BT-549 | STK547622 | 72 | inf | 0.9826 | 0.0068 | 0.0000 | 0.9966 | 0.0100 |
| HCC1419 | 5-(4-fluorophenyl)-3-hydroxy-4-(5-methyl-2-furoyl)-1-(3-pyridinylmethyl)-1,5-dihydro-2H-pyrrol-2-one | 72 | inf | 0.9816 | -0.0058 | 0.0000 | 1.0000 | 0.0100 |
| BT-20 | IU1 | 72 | inf | 1.1490 | -0.1850 | 0.0000 | 1.0000 | 0.0100 |
| HCC1428 | HY-17542 | 72 | inf | 0.7557 | 0.0179 | 0.0000 | 0.9697 | 0.0100 |
| BT-20 | STK547622 | 72 | inf | 1.1526 | -0.0532 | 0.0000 | 1.0000 | 0.0100 |
| HCC1428 | 5-(4-fluorophenyl)-3-hydroxy-4-(5-methyl-2-furoyl)-1-(3-pyridinylmethyl)-1,5-dihydro-2H-pyrrol-2-one | 72 | inf | 0.9183 | 0.0941 | 0.0000 | 0.9165 | 0.0100 |
| HCC1428 | z-VAE(OMe)-fmk | 72 | inf | 0.9944 | 0.0566 | 0.0000 | 0.9577 | 0.0100 |
| CAMA-1 | z-VAE(OMe)-fmk | 72 | inf | 0.9619 | 0.0262 | 0.0000 | 0.9726 | 0.0100 |
| HCC1428 | USP7-IN-1 | 72 | inf | 0.6846 | 0.0667 | 0.0000 | 0.9252 | 0.0100 |
| HCC1428 | GW7647 | 72 | inf | 0.6988 | -0.0012 | 0.0000 | 0.9685 | 0.0100 |
| BT-549 | 5-(4-fluorophenyl)-3-hydroxy-4-(5-methyl-2-furoyl)-1-(3-pyridinylmethyl)-1,5-dihydro-2H-pyrrol-2-one | 72 | inf | 0.9516 | 0.0187 | 0.0000 | 0.9793 | 0.0100 |
| BT-20 | GW7647 | 72 | inf | 0.7093 | -0.0625 | 0.0000 | 1.0000 | 0.0100 |
| HCC202 | STK547622 | 72 | inf | 0.8807 | 0.0217 | 0.0000 | 0.9799 | 0.0100 |
| HCC202 | 5-(4-fluorophenyl)-3-hydroxy-4-(5-methyl-2-furoyl)-1-(3-pyridinylmethyl)-1,5-dihydro-2H-pyrrol-2-one | 72 | inf | 0.7899 | 0.0919 | 0.0000 | 0.9166 | 0.0100 |